Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study

BACKGROUND: The mortality rate remains high among patients with coinfection with Pneumocystis pneumonia (PCP) and HIV. The timing for initiation of antiretroviral therapy (ART) after a diagnosis of moderate to severe PCP remains controversial, however. We therefore designed the present study to dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yan-Ming, Li, Yao, Lu, Yan-Qiu, Liu, Min, Nie, Jing-Min, Yuan, Jing, Harypursat, Vijay, Zhou, Yi-Hong, Qin, Yuan-Yuan, Chen, Xiao-Hong, Zhang, Yu-Lin, Zhang, De-Fa, Wang, Ni, Chen, Hui, Tian, Qun, Zhou, Yang, Qin, Ying-Mei, Yang, Xin-Ping, Chen, Yao-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402404/
https://www.ncbi.nlm.nih.gov/pubmed/36008855
http://dx.doi.org/10.1186/s12890-022-02118-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402404/
https://www.ncbi.nlm.nih.gov/pubmed/36008855
http://dx.doi.org/10.1186/s12890-022-02118-4

Ejemplares similares